Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RAF1 | P04049 | 2/20 | 0.53 |
| ▸ | KDR | P35968 | 14/20 | 0.50 |
| ▸ | BRAF | P15056 | 10/20 | 0.50 |
| ▸ | FGFR1 | P11362 | 1/20 | 0.50 |
| ▸ | MAPK14 | Q16539 | 7/20 | 0.49 |
| ▸ | TNNI3K | Q59H18 | 7/20 | 0.49 |
| ▸ | KIT | P10721 | 1/20 | 0.44 |
| ▸ | DDR1 | Q08345 | 1/20 | 0.44 |
| ▸ | DDR2 | Q16832 | 1/20 | 0.44 |
| ▸ | MAP2K7 | O14733 | 1/20 | 0.42 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5337876 | 0.92 | RAF1 (0.61) | RAF1KDRBRAFFGFR1MAPK14 | |
| SCHEMBL5342028 | 0.90 | KDR (0.58) | RAF1KDRBRAFFGFR1MAPK14 | |
| SCHEMBL5350951 | 0.90 | KDR (0.54) | RAF1KDRBRAFFGFR1MAPK14 | |
| SCHEMBL5342064 | 0.84 | KDR (0.46) | RAF1KDRBRAFMAPK14TNNI3K | |
| SCHEMBL5338918 | 0.83 | KDR (0.68) | KDRBRAFFGFR1MAPK14KIT | |
| SCHEMBL5419476 | 0.81 | KDR (0.54) | KDRBRAFMAPK14TNNI3KMAP2K7 | |
| SCHEMBL14447654 | 0.78 | KDR (0.45) | KDRBRAFMAPK14TNNI3KMAP2K7 | |
| SCHEMBL4929645 | 0.77 | KDR (0.65) | RAF1KDRBRAFFGFR1MAPK14 | |
| SCHEMBL5453242 | 0.77 | MCHR1 (0.46) | KDRBRAFMAPK14TNNI3K | |
| SCHEMBL4769351 | 0.76 | KDR (0.64) | RAF1KDRBRAFFGFR1MAPK14 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2007076473-A2 | SUBSTITUTED PYRIMIDINYLOXY UREAS USEFUL AS INHIBITORS OF PROTEIN KINASES | KALYPSYS, INC. (US) | 2007-07-05 | — | — | WO | disclosed |
| US-20070155764-A1 | NOVEL SUBSTITUTED PYRIMIDINYLOXY UREAS USEFUL AS INHIBITORS OF PROTEIN KINASES | KALYPSYS, INC. (US) | 2007-07-05 | — | — | US | disclosed |
| US-20070155764-A1 | NOVEL SUBSTITUTED PYRIMIDINYLOXY UREAS USEFUL AS INHIBITORS OF PROTEIN KINASES | KALYPSYS, INC. (US) | 2007-07-05 | — | — | US | disclosed |
| US-20070155764-A1 | NOVEL SUBSTITUTED PYRIMIDINYLOXY UREAS USEFUL AS INHIBITORS OF PROTEIN KINASES | KALYPSYS, INC. (US) | 2007-07-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070155764-A1 | NOVEL SUBSTITUTED PYRIMIDINYLOXY UREAS USEFUL AS INHIBITORS OF PROTEIN KINASES | BRAF, ARAF, RAF1 | RAF1 3/4885KDR 555/4885BRAF 1/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.